Pancreatic cancer has long been one of the hardest cancers to treat. Most cases are found late, after the disease has already spread, and the options that follow first-line chemotherapy have offered only modest benefit. So when results from a large global trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published in the New England Journal of Medicine, the response among oncologists was unusually strong.
The drug at the centre of this attention is daraxonrasib. Daraxonrasib is a new oral drug for pancreatic cancer. It blocks faulty RAS proteins, the main driver behind most pancreatic tumours. In a large phase 3 trial, it nearly doubled survival compared with chemotherapy. It isn’t fully approved yet, but it’s available through expanded access for some previously treated patients. If you or a loved one has pancreatic cancer, ask your oncologist about RAS testing and whether this option could fit. This blog explains what daraxonrasib is, how it works, and what the trial actually showed.
What is daraxonrasib?
Daraxonrasib (research code RMC-6236) is an oral targeted drug for pancreatic cancer. It blocks RAS, a faulty protein that tells cancer cells to keep growing. RAS drives more than 90 percent of pancreatic tumours. Unlike chemotherapy, which attacks fast-dividing cells all over the body, daraxonrasib aims at the exact signal feeding the cancer.
RAS works like a stuck “on” switch inside the cell. When it’s active, it keeps sending growth signals that let the tumour spread. Daraxonrasib is what scientists call a RAS(ON) multi-selective inhibitor. It first attaches to a helper protein in the cell, then locks onto the active form of RAS and shuts that signal down. It can target both mutated and normal RAS.
Because it’s a pill, patients take it at home once a day. That’s a real shift from chemotherapy, which usually means hospital visits and an intravenous drip. If you want to understand how faulty genes drive tumours in the first place, our guide to genetic changes in cancer explains it in plain language.
5 easy Steps to Get Treated Abroad
Share Case Details
Get Expert Opinion and Hospital Quotes
Get Visa Invitation & Hotel Recommendations
Get Received At Airport and Start Your Treatment
Travel Back and Get Followups Through Us
Chat on WhatsAppHow Much Does Daraxonrasib Improve Survival?
The findings come from RASolute 302, a Phase 3 trial in patients with previously treated metastatic pancreatic cancer, comparing daraxonrasib against the standard chemotherapy options used worldwide.
According to the results reported by the trial investigators:
- Median overall survival was 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy.
- This corresponds to roughly a 60 per cent reduction in the risk of death (hazard ratio 0.40).
- Median progression-free survival was about 7.2 months versus 3.6 months with chemotherapy.
- Patients on daraxonrasib reported fewer serious side effects and a longer delay before worsening of cancer-related pain and quality of life.
The lead investigator, Dr Brian Wolpin of the Dana-Farber Cancer Institute, noted that patients with metastatic pancreatic cancer urgently need treatments that improve both survival and quality of life. Several investigators described the data as among the most significant seen in this disease in many years.
Why Pancreatic Cancer Has Been So Hard to Treat
Two problems have held back progress for decades. The first is timing. Pancreatic cancer often grows quietly and is found late, after it has already spread. By then, surgery is rarely an option, and chemotherapy buys limited time.
The second problem is RAS itself. Scientists knew for more than 40 years that RAS drove most pancreatic tumours. The trouble was that nobody could make a drug to block it safely. RAS was widely labelled “undruggable.” Its surface is smooth, with no easy pocket for a drug to grab onto.
Daraxonrasib gets around this by using a helper protein to reach the active form of RAS. That clever route is what sets it apart from older attempts. It also explains why patient advocacy groups like the Pancreatic Cancer Action Network describe these results as a major change for the field. If you’ve been told options are limited, it’s often worth getting a second opinion before deciding what comes next.
Is Daraxonrasib Approved, and When Could It Be Widely Available?
Daraxonrasib is not yet approved anywhere in the world. It still counts as an investigational drug. The United States Food and Drug Administration has given it breakthrough therapy and orphan drug status, and has cleared an expanded access protocol so some patients can use it before full approval.
The drug’s maker has said it plans to file for full approval and is moving quickly through a priority review pathway. Reports suggest a decision could come later in 2026, though no date is confirmed. Approval in other countries would follow its own timelines, so availability will differ from one place to another.
Daraxonrasib is also being studied in other RAS-driven cancers, including lung and colorectal cancer. If those trials succeed, its role could grow well beyond pancreatic cancer. For now, the practical step for patients is to confirm RAS status and ask a specialist whether expanded access or a trial is open to them.
Conclusion
Daraxonrasib stands out for a simple reason: it gave patients with advanced pancreatic cancer something this disease has rarely offered, which is more time. Nearly doubling survival in a phase 3 trial is the kind of result doctors wait years to see.
Three things are worth remembering. The drug targets RAS, the faulty switch behind most pancreatic tumours. It nearly doubled survival against chemotherapy in previously treated patients. And it points to a future where pancreatic cancer is treated by its genetics, not just by chemotherapy.
It’s also worth being clear about where things stand. Daraxonrasib is still an investigational drug. Regulators haven’t approved it yet, and the trial studied it in the second-line setting, after an earlier treatment had stopped working. The drug has received Breakthrough Therapy and Orphan Drug designations in the United States, and was selected for the FDA’s Commissioner’s National Priority Voucher program, a pathway meant to speed up review. Further trials are underway in first-line and earlier-stage disease. For now, it can be reached only through expanded access or a clinical trial, not as a standard treatment.
As with any new therapy, longer follow-up and regulatory review will shape how and when it can be used. But the direction is clear, and that’s reason for hope.
If pancreatic cancer is part of your story, the next step is simple. Talk to a cancer specialist about RAS testing and your treatment options. Book a consultation with Cancer Rounds and get a personalised plan built around your reports. The right plan starts with the right conversation.
